Discoveries in Lymphoma
Discoveries in Lymphoma
Source/Disclosures
Source:

Sehgal A, et al. Abstract 8040. Presented at: ASCO20 Virtual Scientific Program; May 29-31, 2020.

Disclosures: Sehgal reports receiving research funding from Juno Therapeutics, Kite/Gilead and Merck.
July 09, 2020
1 min read
Save

Lisocabtagene maraleucel CAR T shows durable response in large B-cell NHL

Source/Disclosures
Source:

Sehgal A, et al. Abstract 8040. Presented at: ASCO20 Virtual Scientific Program; May 29-31, 2020.

Disclosures: Sehgal reports receiving research funding from Juno Therapeutics, Kite/Gilead and Merck.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In updated results of the pilot study, presented during the ASCO2020 Virtual Scientific Program, researchers showed that lisocabtagene maraleucel induced durable response as a second-line treatment in large B-cell non-Hodgkin lymphoma.

“These data suggest that elderly and/or comorbid patients with relapsed/refractory aggressive large B-cell non-Hodgkin lymphoma who are ineligible for high-dose chemotherapy and hematopoietic stem cell transplant can receive [lisocabtagene maraleucel] in the second-line setting,” Alison Sehgal, MD, from the University of Pittsburgh, said in her recorded presentation. “In this study, treatment with [lisocabtagene maraleucel] resulted in durable responses, including complete response and no patients experienced grade 3 or higher cytokine release syndrome.”

Sehgal outlined that the objective of the study as determining the safety, anti-tumor activity and pharmacokinetics of lisocabtagene maraleucel (liso-cel; Bristol-Myers Squibb) in patients with relapsed or refractory large B-cell NHL who are ineligible for other treatments due to age, comorbidities or ECOG performance status.

Eligibility was dependent on receiving only one prior line of immunotherapy with an anthracycline and a CD-20 targeted agent, she added. Forty-one patients underwent leukapheresis and 29 received liso-cel and were assessed for efficacy; 79% of those had at least one indicator for poor prognosis.

Sehgal reported that 69% of patients experienced a grade 3 or 4 treatment-emergent adverse event and while two patients experienced grade 3 neurologic events, none had cytokine release syndrome of grade 3 or higher.

“The objective response rate was 89% with a complete response rate of 56%,” she said. “The Kaplan-Meier estimated probability of response at months 3 and 6 were 63% and 53%, respectively.”

By day 30, all evaluable patients achieved early objective response while eight patients maintained durable response at 3 months and four remained in complete response for 6 months, Sehgal added. The median time to peak CAR T-cell levels was 11 days.

“These data support further evaluation of liso-cel in the second-line setting for patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma who are ineligible for hematopoietic stem cell transplant,” she said.